A Phase 1 First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

PURPOSE: TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase 1, open label study assessed safety, pharmacokinetics, and antitumor activity of TRC105 in patients with advanced refractory solid tumors. PATIENTS AND METHODS: Patients received escalating...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rosen, Lee S., Hurwitz, Herbert I., Wong, Michael K., Goldman, Jonathan, Mendelson, David S., Figg, William D., Spencer, Shawn, Adams, Bonne J., Alvarez, Delia, Seon, Ben K., Theuer, Charles P., Leigh, Bryan R., Gordon, Michael S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3432706/
https://ncbi.nlm.nih.gov/pubmed/22767667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0098
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky